Long‐term use of deferiprone significantly enhances left‐ventricular ejection function in thalassemia major patients
Year: 2012
Type: article
Abstract: A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].
Source: American Journal of Hematology
DOI: 10.1002/ajh.23219
Authors: Aurelio Maggio, Angela Vitrano, Gaetano Lucania, Marcello Capra, Liana Cuccia, Francesco Gagliardotto, Lorella Pitrolo, Luciano Prossomariti, Aldo Filosa, Vincenzo Caruso, Calogera Gerardi, Saveria Campisi, Paolo Cianciulli, Michele Rizzo, Giuseppe D'Ascola, Angela Ciancio, Rosario Di Maggio, Giuseppina Calvaruso, Gaetano Restivo Pantalone, Paolo Rigano
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1983666413